Ken Griffin Tenaya Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$1.93 - $3.99 $36,477 - $75,411	-18,900 Reduced 95.45%	900 $1,000
Q2 2024 Aug 14, 2024	SELL	$2.72 - $4.99 $3,808 - $6,986	-1,400 Reduced 6.6%	19,800 $61,000
Q1 2024 May 15, 2024	BUY	$2.88 - $6.8 $38,592 - $91,120	13,400 Added 171.79%	21,200 $110,000
Q4 2023 Feb 14, 2024	SELL	$1.73 - $3.39 $7,612 - $14,916	-4,400 Reduced 36.07%	7,800 $25,000
Q3 2023 Nov 14, 2023	SELL	$2.55 - $5.65 $43,095 - $95,485	-16,900 Reduced 58.08%	12,200 $31,000
Q2 2023 Aug 14, 2023	BUY	$2.64 - $7.64 $43,032 - $124,532	16,300 Added 127.34%	29,100 $170,000
Q1 2023 May 15, 2023	BUY	$1.92 - $3.59 $24,192 - $45,234	12,600 Added 6300.0%	12,800 $36,000
Q4 2022 Feb 14, 2023	BUY	$1.68 - $3.19 $336 - $638	200 New	200 $0

56.3M

900

400

Ticker TNYA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,364,700
Market Cap $69.1M
Description
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hyp...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.